GlassScriptPhysician profile
Veronica J Carreon
NPI 1548595937
$4,142.66
in general payments reported to CMS, 2019-2025
23 companies · $729 in 2025
The $729 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $276 · 2022: $518 · 2023: $1,812 · 2024: $808 · 2025: $729.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,695 · Travel and Lodging: $653.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,694.92 |
| Travel and Lodging | $653.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neuronetics, INC. | $1,165.60 | 2023 | Neurostar Tms Therapy System |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $712.98 | 2021-2025 | Xifaxan |
| Gilead Sciences, INC. | $595.96 | 2021-2025 | Livdelzi |
| Abbvie INC. | $320.20 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $260.10 | 2022-2025 | Dificid, Zerbaxa, Recarbrio |
| Eisai INC. | $243.09 | 2022-2024 | |
| Madrigal Pharmaceuticals | $165.88 | 2024-2025 | Rezdiffra |
| Intercept Pharmaceuticals, INC. | $103.23 | 2024-2025 | |
| Orphalan INC | $64.79 | 2024-2025 | Cuvrior |
| Takeda Pharmaceuticals U.S.A., INC. | $59.41 | 2025 | Livtencity |
| Ipsen Biopharmaceuticals, INC | $58.96 | 2025 | Iqirvo |
| Novo Nordisk INC | $58.72 | 2025 | Wegovy |
| Incyte Corporation | $57.84 | 2022-2024 | Monjuvi, Pemazyre |
| Mallinckrodt Hospital Products INC. | $51.06 | 2025 | Terlivaz |
| Celltrion USA INC. | $34.85 | 2024-2025 | Vegzelma |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $34.62 | 2021-2024 | Heplisav-B |
| Intra-Sana Laboratories | $28.97 | 2022 | |
| Alexion Pharmaceuticals, INC. | $24.32 | 2022 | |
| Teleflex LLC | $23.10 | 2022 | |
| Eton Pharmaceuticals, INC. | $22.41 | 2025 | Galzin, Carglumic Acid, Nitisinone |
| Kerecis Limited | $22.01 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Genzyme Corporation | $20.13 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $14.43 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Veronica Carreon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.